Le Tourneau C
Institut Curie, 26, rue d'Ulm, 75248 Paris cedex 05, France.
Bull Cancer. 2010 Dec;97(12):1453-66. doi: 10.1684/bdc.2010.1226.
The emergence of molecularly targeted therapy did not spare head and neck cancers. Head and neck squamous cell carcinomas (HNSCC) were indeed one of the first tumor types to get a molecularly targeted agent approved (cetuximab, a monoclonal antibody targeting EGFR), not only in the recurrent or metastatic setting but also in the locally advanced setting. However, the development of molecularly targeted agents inhibiting non-EGFR targets appears to be complex. This article summarizes recent data on molecularly targeted agents in most frequent head and neck cancers including HNSCC, nasopharyngeal carcinoma and adenoid cystic carcinoma of salivary glands. Challenges for the development of these agents are then discussed.
分子靶向治疗的出现并未放过头颈癌。头颈部鳞状细胞癌（HNSCC）确实是最早获得分子靶向药物批准的肿瘤类型之一（西妥昔单抗，一种靶向表皮生长因子受体的单克隆抗体），不仅在复发或转移的情况下，而且在局部晚期的情况下。然而，抑制非表皮生长因子受体靶点的分子靶向药物的开发似乎很复杂。本文总结了关于最常见的头颈癌，包括HNSCC、鼻咽癌和涎腺腺样囊性癌的分子靶向药物的最新数据。然后讨论了这些药物开发面临的挑战。
